These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15008033)

  • 41. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE
    J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study.
    Lawton J; Peel E; Parry O; Douglas M
    Diabet Med; 2008 Apr; 25(4):491-5. PubMed ID: 18294222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perceptions and experiences of taking oral medications for the treatment of Type 2 diabetes mellitus: a systematic review and meta-synthesis of qualitative studies.
    McSharry J; McGowan L; Farmer AJ; French DP
    Diabet Med; 2016 Oct; 33(10):1330-8. PubMed ID: 27150899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral antidiabetic drug use and associated health outcomes in cancer patients.
    Tan X; Feng X; Chang J; Higa G; Wang L; Leslie D
    J Clin Pharm Ther; 2016 Oct; 41(5):524-31. PubMed ID: 27453485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding adherence to medications in type 2 diabetes care and clinical trials to overcome barriers: a narrative review.
    Tiktin M; Celik S; Berard L
    Curr Med Res Opin; 2016; 32(2):277-87. PubMed ID: 26565758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucose Management in Hospitalized Patients.
    Kodner C; Anderson L; Pohlgeers K
    Am Fam Physician; 2017 Nov; 96(10):648-654. PubMed ID: 29431385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis.
    Han S; Iglay K; Davies MJ; Zhang Q; Radican L
    Curr Med Res Opin; 2012 Jun; 28(6):969-77. PubMed ID: 22494018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature.
    Stephens JM; Botteman MF; Hay JW
    J Manag Care Pharm; 2006 Mar; 12(2):130-42. PubMed ID: 16515371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
    Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fixed-Dose and Fixed-Ratio Combination Therapies in Type 2 Diabetes.
    Schlosser R
    Can J Diabetes; 2019 Aug; 43(6):440-444. PubMed ID: 31375179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adherence to therapies in patients with type 2 diabetes.
    García-Pérez LE; Alvarez M; Dilla T; Gil-Guillén V; Orozco-Beltrán D
    Diabetes Ther; 2013 Dec; 4(2):175-94. PubMed ID: 23990497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes.
    Christofides EA
    Clin Diabetes; 2019 Jul; 37(3):234-241. PubMed ID: 31371854
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).
    Gao B; Gao W; Wan H; Xu F; Zhou R; Zhang X; Ji Q
    Diabetes Obes Metab; 2022 Jun; 24(6):991-999. PubMed ID: 35112779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study.
    Inagaki N; Sano H; Seki Y; Kuroda S; Kaku K
    J Diabetes Investig; 2018 Mar; 9(2):354-359. PubMed ID: 28836351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of attitudes and intentions in predicting adherence to oral diabetes medications.
    Fai EK; Anderson C; Ferreros V
    Endocr Connect; 2017 Feb; 6(2):63-70. PubMed ID: 28087609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What's next after metformin? focus on sulphonylurea: add-on or combination therapy.
    Lim PC; Chong CP
    Pharm Pract (Granada); 2015; 13(3):606. PubMed ID: 26445623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia.
    Ahmad NS; Ramli A; Islahudin F; Paraidathathu T
    Patient Prefer Adherence; 2013; 7():525-30. PubMed ID: 23814461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The reality of dietary compliance in the management of phenylketonuria.
    MacDonald A; Gokmen-Ozel H; van Rijn M; Burgard P
    J Inherit Metab Dis; 2010 Dec; 33(6):665-70. PubMed ID: 20373144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.
    Cramer JA; Benedict A; Muszbek N; Keskinaslan A; Khan ZM
    Int J Clin Pract; 2008 Jan; 62(1):76-87. PubMed ID: 17983433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to oral therapy for type 2 diabetes: opportunities for enhancing glycemic control.
    Bartels D
    J Am Acad Nurse Pract; 2004 Jan; 16(1):8-16. PubMed ID: 15008033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.